GLP-1RAs: Benefits and Considerations for Type 2 Diabetes and CKD

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are crucial for managing blood sugar and promoting weight loss in individuals with type 2 diabetes (T2D). Some formulations also reduce cardiovascular risks in high-risk patients. Furthermore, there is emerging evidence suggesting kidney-protective benefits, particularly for T2D patients with chronic kidney disease (CKD).

GLP-1RAs mimic natural glucagon-like peptide-1, stimulating insulin production in response to glucose, suppressing glucagon release, slowing gastric emptying, and increasing satiety. These combined actions lead to improved blood sugar control and weight management.

A significant advantage of GLP-1RAs is their low risk of causing hypoglycemia, which is beneficial for older adults and those with CKD. However, common gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation may occur. These are generally manageable through gradual dose escalation and patient education. Close monitoring of hydration is essential for patients with severe CKD to prevent kidney function deterioration.